- Home
- MDCX vs GDTC Comparison
MDCX vs GDTC Comparison
Compare MDCX & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDCX
- GDTC
- Stock Information
- Founded
- MDCX 2008
- GDTC 2018
- Country
- MDCX Canada
- GDTC Singapore
- Employees
- MDCX N/A
- GDTC N/A
- Industry
- MDCX
- GDTC Biotechnology: Pharmaceutical Preparations
- Sector
- MDCX
- GDTC Health Care
- Exchange
- MDCX Nasdaq
- GDTC Nasdaq
- Market Cap
- MDCX 44.0M
- GDTC 28.0M
- IPO Year
- MDCX N/A
- GDTC 2023
- Fundamental
- Price
- MDCX $3.10
- GDTC $2.21
- Analyst Decision
- MDCX Strong Buy
- GDTC Buy
- Analyst Count
- MDCX 2
- GDTC 1
- Target Price
- MDCX $23.50
- GDTC $5.00
- AVG Volume (30 Days)
- MDCX 480.6K
- GDTC 6.5K
- Earning Date
- MDCX 08-22-2025
- GDTC 01-01-0001
- Dividend Yield
- MDCX N/A
- GDTC N/A
- EPS Growth
- MDCX N/A
- GDTC N/A
- EPS
- MDCX N/A
- GDTC N/A
- Revenue
- MDCX N/A
- GDTC $368,838.00
- Revenue This Year
- MDCX N/A
- GDTC $5.37
- Revenue Next Year
- MDCX N/A
- GDTC N/A
- P/E Ratio
- MDCX N/A
- GDTC N/A
- Revenue Growth
- MDCX N/A
- GDTC N/A
- 52 Week Low
- MDCX $1.80
- GDTC $1.20
- 52 Week High
- MDCX $8.94
- GDTC $4.05
- Technical
- Relative Strength Index (RSI)
- MDCX N/A
- GDTC 49.36
- Support Level
- MDCX N/A
- GDTC $2.09
- Resistance Level
- MDCX N/A
- GDTC $2.35
- Average True Range (ATR)
- MDCX 0.00
- GDTC 0.10
- MACD
- MDCX 0.00
- GDTC 0.00
- Stochastic Oscillator
- MDCX 0.00
- GDTC 50.00
About MDCX Medicus Pharma Ltd. Common Stock
Medicus Pharma Ltd is a clinical-stage holding company focused on investing in and accelerating novel life sciences and bio-technology companies through FDA-approved clinical trials. The Company focuses on meeting the unmet need to improve patient safety and efficacy.
About GDTC CytoMed Therapeutics Limited
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The development of its novel technologies has been inspired by the clinical success of existing CAR-T cells in treating hematological malignancies as well as the current clinical limitations and commercial challenges in extrapolating the CAR-T principle into the treatment of solid tumors. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.